GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (NAS:AZN) » Definitions » Cyclically Adjusted FCF per Share

AZN (AstraZeneca) Cyclically Adjusted FCF per Share : $1.32 (As of Sep. 2024)


View and export this data going back to 1993. Start your Free Trial

What is AstraZeneca Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

AstraZeneca's adjusted free cash flow per share for the three months ended in Sep. 2024 was $0.648. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $1.32 for the trailing ten years ended in Sep. 2024.

During the past 12 months, AstraZeneca's average Cyclically Adjusted FCF Growth Rate was 4.80% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 6.80% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -3.60% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -5.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of AstraZeneca was 39.60% per year. The lowest was -15.00% per year. And the median was 2.55% per year.

As of today (2024-12-14), AstraZeneca's current stock price is $66.58. AstraZeneca's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2024 was $1.32. AstraZeneca's Cyclically Adjusted Price-to-FCF of today is 50.44.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of AstraZeneca was 73.79. The lowest was 14.59. And the median was 37.37.


AstraZeneca Cyclically Adjusted FCF per Share Historical Data

The historical data trend for AstraZeneca's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Cyclically Adjusted FCF per Share Chart

AstraZeneca Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.21 1.04 0.96 1.09 1.18

AstraZeneca Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.15 1.18 1.20 1.24 1.32

Competitive Comparison of AstraZeneca's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted Price-to-FCF falls into.



AstraZeneca Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AstraZeneca's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=0.648/133.5000*133.5000
=0.648

Current CPI (Sep. 2024) = 133.5000.

AstraZeneca Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 0.543 99.900 0.726
201503 -0.453 99.600 -0.607
201506 0.172 100.100 0.229
201509 0.479 100.200 0.638
201512 0.014 100.400 0.019
201603 0.351 100.400 0.467
201606 -0.324 101.000 -0.428
201609 0.176 101.500 0.231
201612 0.521 102.200 0.681
201703 -0.117 102.700 -0.152
201706 -0.032 103.500 -0.041
201709 0.746 104.300 0.955
201712 0.176 105.000 0.224
201803 -0.187 105.100 -0.238
201806 -0.116 105.900 -0.146
201809 0.079 106.600 0.099
201812 0.716 107.100 0.892
201903 -0.452 107.000 -0.564
201906 -0.037 107.900 -0.046
201909 0.290 108.400 0.357
201912 0.377 108.500 0.464
202003 -0.090 108.600 -0.111
202006 0.024 108.800 0.029
202009 0.426 109.200 0.521
202012 0.476 109.400 0.581
202103 0.555 109.700 0.675
202106 0.204 111.400 0.244
202109 0.354 112.400 0.420
202112 0.224 114.700 0.261
202203 0.919 116.500 1.053
202206 0.226 120.500 0.250
202209 0.583 122.300 0.636
202212 0.591 125.300 0.630
202303 0.533 126.800 0.561
202306 0.396 129.400 0.409
202309 0.716 130.100 0.735
202312 0.457 130.500 0.468
202403 0.282 131.600 0.286
202406 0.775 133.000 0.778
202409 0.648 133.500 0.648

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


AstraZeneca  (NAS:AZN) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

AstraZeneca's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=66.58/1.32
=50.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of AstraZeneca was 73.79. The lowest was 14.59. And the median was 37.37.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


AstraZeneca Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca Business Description

Industry
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.